Skip to main content
logo
Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
84.70
+1.97 (2.39%)
Aug 4, 2026, 10:58 AM EDT - Market open

Inhibrx Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-1.30.21.82.197.23
Revenue Growth
-550.00%-88.89%-17.88%-69.69%-43.89%
Gross Profit
-1.30.21.82.197.23
Operating Income
-123.05-135.03-331.45-219.22-129.12-76.56
Net Income
-130.19-140.061,688-243-145.23-81.77
Earnings Per Share
-8.39-9.04112.62-20.48-3.62-2.15
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
161.66124.22152.6277.92273.87131.3
Total Debt
180.9107.018.05210.14207.177.18
Net Cash (Debt)
-19.2417.21144.5567.7866.7654.12
Net Cash Growth
--88.09%113.25%1.53%23.35%-40.66%
Net Cash Per Share
-1.241.119.655.751.661.42

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-131.93-129.79-194.41-193.31-115.3-80.32
Capital Expenditures
-0.01-0.03-2.6-4.59-0.69-0.86
Free Cash Flow
-131.94-129.83-197.01-197.9-115.99-81.19
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-100.00%100.00%100.00%100.00%100.00%
Operating Margin
--10386.50%-165724.00%-12178.90%-5890.37%-1058.83%
Pretax Margin
--10773.31%843787.00%-13318.00%-6625.14%-1130.77%
Profit Margin
--10773.50%843786.00%-13408.90%-6625.27%-1130.80%
FCF Margin
--9986.54%-98503.00%-10994.60%-5291.38%-1122.76%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--0.14---
Forward PE
-0.200.20---
PS Ratio
933.54885.871114.641000.02489.70235.48